Public Library of Science
Browse
Fig 4.TIF (1.28 MB)

Market share of AZT, TDF, TAF and DTG in second-line treatment from 2015 to 2025.

Download (1.28 MB)
figure
posted on 2016-10-13, 17:47 authored by Aastha Gupta, Sandeep Juneja, Marco Vitoria, Vincent Habiyambere, Boniface Dongmo Nguimfack, Meg Doherty, Daniel Low-Beer

Market share of AZT, TDF, TAF and DTG in second-line treatment from 2015 to 2025.

History

Usage metrics

    PLOS ONE

    Categories

    Keywords

    first-line treatmentprotease inhibitorsload testingTDF 300 mgForecast Analysis 2015-20252025. UNAIDS estimates 24.7LPVsecond-line treatmentTAF 25 mgtreatment regimensNew AntiretroviralLMICfuture changesPLHIVUNAIDS data sourcesgenerics pipelineEFVART scale-upARV drugsARV marketgenerics manufacturersATVtenofovir alafenamidemarket sharedose ARVsART regimenDTG 50 mgthird-line treatmentforecast analysisHIVTBARV medicinesanti-retroviral treatmentMiddle-Income Countries

    Licence

    CC BY 4.0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC